- Home
- NOM vs MRNS Comparison
NOM vs MRNS Comparison
Compare NOM & MRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOM
- MRNS
- Stock Information
- Founded
- NOM 1993
- MRNS 2003
- Country
- NOM United States
- MRNS United States
- Employees
- NOM N/A
- MRNS N/A
- Industry
- NOM Investment Managers
- MRNS Biotechnology: Pharmaceutical Preparations
- Sector
- NOM Finance
- MRNS Health Care
- Exchange
- NOM Nasdaq
- MRNS Nasdaq
- Market Cap
- NOM 28.0M
- MRNS 29.9M
- IPO Year
- NOM N/A
- MRNS 2014
- Fundamental
- Price
- NOM $11.62
- MRNS $0.54
- Analyst Decision
- NOM
- MRNS Buy
- Analyst Count
- NOM 0
- MRNS 12
- Target Price
- NOM N/A
- MRNS $4.28
- AVG Volume (30 Days)
- NOM 6.9K
- MRNS 3.2M
- Earning Date
- NOM 01-01-0001
- MRNS 03-04-2025
- Dividend Yield
- NOM 3.39%
- MRNS N/A
- EPS Growth
- NOM N/A
- MRNS N/A
- EPS
- NOM N/A
- MRNS N/A
- Revenue
- NOM N/A
- MRNS $31,466,000.00
- Revenue This Year
- NOM N/A
- MRNS $14.97
- Revenue Next Year
- NOM N/A
- MRNS $57.65
- P/E Ratio
- NOM N/A
- MRNS N/A
- Revenue Growth
- NOM N/A
- MRNS 1.63
- 52 Week Low
- NOM $8.52
- MRNS $0.22
- 52 Week High
- NOM $10.48
- MRNS $10.50
- Technical
- Relative Strength Index (RSI)
- NOM 53.96
- MRNS 70.61
- Support Level
- NOM $11.14
- MRNS $0.54
- Resistance Level
- NOM $11.53
- MRNS $0.55
- Average True Range (ATR)
- NOM 0.27
- MRNS 0.01
- MACD
- NOM -0.06
- MRNS 0.01
- Stochastic Oscillator
- NOM 44.25
- MRNS 69.57
About NOM Nuveen Missouri Quality Municipal Income Fund
Nuveen Missouri Quality Municipal Income Fund is a diversified, closed-end management investment company operating in United States. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Missouri state income taxes; its secondary investment objective is the enhancement of portfolio value. The fund invests in municipal securities as well as floating rate securities as well as derivatives such as futures, options and swap contracts to the necessary extent. Nuveen Fund Advisors, LLC acts as an investment adviser of the company.
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.